Trial
NCT00448539
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
—
Condition
Refractory Partial Onset Seizures
Intervention
Rufinamide
Why stopped
The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-22